Amenorrhea Diagnosis and Management

Definitions and Diagnostic Criteria

• Primary amenorrhea is defined as the absence of menarche by age 15 years, or by age 13 years in the absence of secondary sexual characteristics 1
• Secondary amenorrhea is defined as the cessation of previously established menstruation for longer than 6 months 2
• Secondary amenorrhea affects approximately 3-4% of women in the general population 2

Etiology

• Delayed puberty is a cause of primary amenorrhea 3
• Functional Hypothalamic Amenorrhea (FHA) accounts for 20-35% of secondary amenorrhea cases 2
• Polycystic Ovary Syndrome (PCOS) is one of the most common causes of secondary amenorrhea 2
• Hyperprolactinemia accounts for approximately 20% of secondary amenorrhea cases 2
• Primary Ovarian Insufficiency (POI) is a cause of secondary amenorrhea 2
• Thyroid dysfunction is a cause of secondary amenorrhea 2

Diagnostic Approach

• A thorough history focusing on growth and development patterns, nutritional status, exercise habits, and psychological stressors is recommended for primary amenorrhea evaluation 1
• Assessment of secondary sexual characteristics development is recommended for primary amenorrhea evaluation 1
• First-line laboratory tests for primary amenorrhea evaluation include FSH, LH, prolactin, and TSH levels 1
• Pelvic ultrasound is recommended to assess uterine and ovarian anatomy in primary amenorrhea evaluation 1
• A pregnancy test is the first step in secondary amenorrhea evaluation 2
• Initial laboratory evaluation for secondary amenorrhea includes serum FSH, LH, prolactin, and TSH levels 2
• Pelvic ultrasound is recommended to evaluate for polycystic ovarian morphology and uterine abnormalities in secondary amenorrhea evaluation 2
• Progestin challenge test is recommended to determine estrogen status in secondary amenorrhea evaluation 2
• Additional testing may include androgen profile for suspected PCOS in secondary amenorrhea evaluation 2

Clinical Considerations and Complications

• Delayed puberty requires careful monitoring and potential intervention 3
• Patients with FHA are at risk for decreased bone density and should be evaluated for eating disorders 2, 4
• Athletes with amenorrhea require evaluation for Relative Energy Deficiency in Sport (RED-S) 4
• DXA scan for bone mineral density assessment is recommended for patients with amenorrhea lasting >6 months 1
• Low estrogen levels in secondary amenorrhea increase risk for decreased bone mineral density and stress fractures 4

Treatment Considerations

• FHA may require addressing underlying stressors, nutritional deficiencies, or excessive exercise 2
• Estrogen replacement therapy may be necessary for patients with low estrogen levels to prevent long-term complications 4

Management of Secondary Amenorrhea in Adolescents

Understanding Normal Post-Menarchal Patterns

• In adolescents, normal menstrual cycles range between 21-45 days, which is wider than the adult range of 21-35 days 5

Initial Management Approach

• Address the stress factor through counseling about stress management, adequate nutrition, and appropriate activity levels, as recommended by the British Journal of Sports Medicine 5
• Screen for eating disorders and excessive exercise, as these are common causes of functional hypothalamic amenorrhea (FHA) in adolescents, according to the British Journal of Sports Medicine 6
• Assess nutritional status and energy availability, particularly looking for signs of low energy availability that can disrupt the hypothalamic-pituitary-gonadal axis, as suggested by the British Journal of Sports Medicine 5

Critical Red Flags Requiring Earlier Evaluation

• Signs of eating disorder or significant weight loss require earlier evaluation, as stated by the British Journal of Sports Medicine 6
• Galactorrhea suggesting hyperprolactinemia is a critical red flag, according to the Journal of Neurology, Neurosurgery and Psychiatry 7
• Headaches or visual changes suggesting pituitary pathology require immediate evaluation, as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 7

Long-Term Monitoring Considerations

• Consider DXA scan for bone mineral density assessment if amenorrhea extends beyond 6 months despite addressing stressors, as suggested by the British Journal of Sports Medicine 6

Common Pitfalls to Avoid

• Do not assume all amenorrhea in athletes or stressed adolescents is benign, as other pathology must be excluded, according to the British Journal of Sports Medicine 6
• Do not overlook eating disorders, as adolescents may minimize or deny disordered eating behaviors, as stated by the British Journal of Sports Medicine 5, 6

Evaluation and Management of Primary Amenorrhea

Initial Assessment and Diagnostic Approach

• The American College of Obstetricians and Gynecologists recommends performing Tanner staging to determine pubertal development status in patients with primary amenorrhea 8
• If no breast development by age 13 years, this represents delayed puberty and requires earlier intervention, according to the American Academy of Pediatrics 9
• If breast development has occurred but no menarche by age 16, or if there is failure to progress through puberty for ≥12 months, proceed with full evaluation, as suggested by the Society for Adolescent Health and Medicine 9

Diagnostic Workup and Management

• The Endocrine Society recommends ordering estradiol level as part of the initial laboratory testing for primary amenorrhea 8
• The American College of Obstetricians and Gynecologists suggests initiating estrogen replacement therapy with cyclic progestogen to induce menstrual cycles and prevent bone loss in patients with hypogonadotropic hypogonadism 8

Management of Amenorrhea in Adolescents

Diagnostic Evaluation and Management

• The Endocrine Society recommends measuring serum prolactin in adolescents presenting with delayed puberty, galactorrhea, visual field loss, growth or pubertal arrest, or menstrual disturbance 10
• A single prolactin measurement taken at any time of day is sufficient to assess hyperprolactinemia, and age-specific and sex-specific prolactin reference ranges should be used 10
• Primary Ovarian Insufficiency (POI) is defined by elevated FSH levels within the menopausal range in patients younger than 40 years with oligo/amenorrhea, and hormonal replacement therapy is indicated to reduce risk of osteoporosis, cardiovascular diseases, and urogenital atrophy 11
• Approximately 8-10% of female survivors of pediatric cancer develop POI, and management with a multidisciplinary team including gynecologists, pediatricians, endocrinologists, dietitians, and psychologists is recommended 11
• In adolescents with pituitary adenomas presenting with amenorrhea, treatment should be performed in specialist centers with pituitary-specific multidisciplinary teams, and collection of outcome data on novel modalities of medical treatment, surgical intervention, and radiotherapy is essential 12

Management of Functional Hypothalamic Amenorrhea

Diagnosis and Screening

• The British Journal of Sports Medicine recommends assessing energy availability by calculating if the patient is consuming >30 kcal/kg fat-free mass/day, and evaluating exercise patterns to identify potential energy deficits 13
• The Journal of Neurology, Neurosurgery and Psychiatry suggests considering mid-luteal progesterone testing to confirm ovulation if cycles resume 14

Prevention of Long-term Complications

• The British Journal of Sports Medicine recommends obtaining a DXA scan for bone mineral density if amenorrhea extends beyond 6 months, as prolonged hypoestrogenic states significantly increase osteoporosis risk 13
• The British Journal of Sports Medicine also notes that 90% of peak bone mass is attained by age 18, making it critical to address amenorrhea in adolescents to prevent long-term bone loss 15

Treatment and Referral

• The British Journal of Sports Medicine suggests referral to endocrinology if the primary care provider is not experienced with FHA treatment 13

Diagnosis and Management of Functional Hypothalamic Amenorrhea

Diagnostic Approach

• The British Journal of Sports Medicine recommends calculating energy availability to determine if the patient is consuming >30 kcal/kg fat-free mass/day 16
• The British Journal of Sports Medicine suggests documenting hours per week and intensity of physical activity to assess exercise patterns 16
• The British Journal of Sports Medicine advises evaluating for restrictive eating, weight loss history, and body mass index through nutritional assessment 16
• Pelvic ultrasound is mandatory to exclude outflow tract obstruction or Müllerian agenesis in cases of primary amenorrhea with normal hormones and normal breast development, as recommended by the Journal of Clinical Oncology 17

Treatment Algorithm

• The British Journal of Sports Medicine recommends increasing caloric intake to achieve >30 kcal/kg fat-free mass/day as primary therapy for functional hypothalamic amenorrhea 16
• The British Journal of Sports Medicine suggests reducing exercise volume and intensity if excessive, with >10 hours/week of intense training warranting evaluation 16
• The British Journal of Sports Medicine advises nutritional counseling by a sports dietitian experienced with energy availability assessment 16
• Recovery of menstrual function may take >6 months despite addressing energy deficits, so patience is required, according to the British Journal of Sports Medicine 16

Hormonal Replacement Therapy

• The British Journal of Sports Medicine recommends considering hormonal replacement therapy if amenorrhea persists >6 months despite addressing stressors and energy availability 16
• The British Journal of Sports Medicine suggests using transdermal estradiol (100 μg patch twice weekly) with cyclic micronized progesterone (200 mg for 12 days/month) for bone health, rather than oral contraceptives 16
• The British Journal of Sports Medicine advises that oral contraceptives do not correct the underlying cause and do not protect bone mineral density as effectively as physiologic estrogen replacement 16

Critical Red Flags

• The British Journal of Sports Medicine recommends evaluating urgently for significant weight loss or signs of eating disorder, which requires multidisciplinary eating disorder team 16
• The Journal of Neurology, Neurosurgery and Psychiatry suggests that hirsutism or acne may indicate PCOS with normal initial labs or late-onset congenital adrenal hyperplasia 18

Common Pitfalls to Avoid

• The British Journal of Sports Medicine advises not to assume amenorrhea in athletes is benign, and other pathology must be excluded even when the clinical picture suggests FHA 16
• The British Journal of Sports Medicine recommends not to prescribe oral contraceptives as first-line therapy, as this masks the problem without addressing the underlying energy deficit and provides false reassurance 16
• The British Journal of Sports Medicine suggests not to overlook eating disorders, as adolescents frequently minimize symptoms, and direct questioning about specific behaviors is necessary 16
• The British Journal of Sports Medicine advises not to delay bone density assessment, and DXA scanning is indicated regardless of age if amenorrhea extends beyond 6 months 16

Treatment of Amenorrhea with Focus on Hypogonadotropic Hypogonadism

Fertility Treatment for Hypogonadotropic Hypogonadism

• The American Society for Reproductive Medicine recommends pulsatile GnRH therapy as the most effective treatment for hypothalamic dysfunction in patients with hypogonadotropic hypogonadism desiring pregnancy 19, 20
• Pulsatile GnRH therapy is more efficient than exogenous gonadotropins in FHA patients, including those with polycystic ovarian morphology (FHA-PCOM), with ovulation rates of 80.8% vs 77.7% 19
• Ongoing pregnancy rates are comparable (70% vs 63% per patient) between FHA-PCOM and FHA-non-PCOM groups treated with pulsatile GnRH therapy 20

Long-Term Monitoring and Complication Prevention

• The Endocrine Society suggests that FHA is associated with a 2-fold increased risk of fractures compared to healthy eumenorrheic women, highlighting the importance of bone health monitoring 21
• About one-third of FHA patients reveal decreased reactive hyperaemia index, consistent with endothelial dysfunction, indicating an increased risk for cardiovascular disease 21

Treatment Approach for Amenorrhea with Low FSH

Diagnostic Confirmation and Etiology Assessment

• Low FSH with amenorrhea indicates hypogonadotropic hypogonadism, which can result from either hypothalamic dysfunction or pituitary failure, with a critical distinction for treatment, according to the American Society for Reproductive Medicine 22
• A LH/FSH ratio <1 is seen in approximately 82% of functional hypothalamic amenorrhea (FHA) cases, while pituitary failure typically shows both hormones suppressed, as reported by the Endocrine Society 22
• Low estradiol (<30 pg/mL) confirms hypoestrogenism and helps differentiate FHA from other causes, as stated by the American College of Obstetricians and Gynecologists 23
• Assessing endometrial thickness via ultrasound, with a thin endometrium (<5 mm) indicating estrogen deficiency and supporting FHA diagnosis, is recommended by the American Institute of Ultrasound in Medicine 22

Primary Treatment Strategy: Address Underlying Causes

• Weight restoration to ensure BMI reaches ≥18.5 kg/m² is essential before considering ovulation induction if fertility is desired, as advised by the American Society for Reproductive Medicine 22

Hormonal Replacement Therapy

• If amenorrhea persists >6 months despite lifestyle modifications, initiating estrogen replacement to prevent long-term complications is recommended by the North American Menopause Society 23
• Critical indication for bone health monitoring, obtaining DXA scan for bone mineral density if amenorrhea extends beyond 6 months, regardless of age, is suggested by the National Osteoporosis Foundation 23

Fertility Treatment (If Pregnancy Desired)

• For patients with hypogonadotropic hypogonadism desiring pregnancy, ensuring BMI ≥18.5 kg/m² and spontaneous menstrual cycles have resumed before offering ovulation induction is necessary, as stated by the American Society for Reproductive Medicine 22
• Avoiding clomiphene citrate as first-line for FHA due to uncertain efficacy and lack of evidence for improved pregnancy rates is recommended by the European Society of Human Reproduction and Embryology 22

Referral Indications

• Referring to endocrinology or gynecology if persistently abnormal hormone levels despite treatment, or signs of pituitary pathology, is advised by the American College of Physicians 23

Primary Amenorrhea with Delayed Puberty and Absent Pubic/Axillary Hair

Diagnostic Considerations

• The absence of pubic and axillary hair despite some breast development is a critical red flag that distinguishes this from simple constitutional delay, according to the American College of Obstetricians and Gynecologists 24, 25

Hormone Replacement Therapy

• The American College of Pediatricians recommends initiating estrogen replacement therapy after gonadectomy (if applicable) or once diagnosis confirmed, with low-dose estrogen (transdermal estradiol 100 μg patch twice weekly preferred over oral) to prevent osteoporosis and cardiovascular complications from prolonged hypoestrogenism 25

Structural Causes of Amenorrhea (PALM‑COEIN)

PALM‑COEIN Structural Etiologies

• Polyps, adenomyosis, leiomyomas, and endometrial malignancy or hyperplasia are recognized structural abnormalities that can lead to amenorrhea according to the PALM‑COEIN classification system. 26

Referral Criteria for Primary Amenorrhea in Adolescents

Urgent Referral Triggers

• Adolescents lacking any signs of puberty by age 13 years and demonstrating elevated follicle‑stimulating hormone levels should be referred promptly to pediatric endocrinology and/or gynecology. 27
• Girls who have not experienced menarche by age 16 years despite the presence of other secondary sexual characteristics meet criteria for immediate specialist evaluation. 27
• Individuals who have failed to initiate puberty or to progress through pubertal stages for a period of ≥ 12 months warrant urgent referral to endocrine and gynecologic services. 27

Evidence‑Based Workup for Secondary Amenorrhea

Laboratory Evaluation

• Measure serum prolactin using a single morning resting sample (avoid post‑exercise or post‑stress collection) to accurately assess hyperprolactinemia. 28

Clinical History

• Document any weight loss > 5 % of body weight over the past 6 months, current body‑mass index, and waist‑to‑hip ratio; a ratio > 0.9 is suggestive of polycystic ovary syndrome (PCOS). 28
• Ask specifically about galactorrhea, hirsutism or acne, and headaches or visual changes, as these symptoms respectively point toward hyperprolactinemia, PCOS/hyperandrogenism, or pituitary pathology. 28

Physical Examination

• Calculate BMI: obesity (BMI > 25 kg/m²) is associated with PCOS, whereas low BMI ( < 18.5 kg/m²) favors functional hypothalamic amenorrhea. 28
• Examine for signs of hyperandrogenism such as male‑pattern hair distribution, acne, and androgenetic alopecia. 28
• Perform nipple expression to detect occult galactorrhea. 28

Diagnostic Algorithms

• When prolactin is elevated, first exclude hypothyroidism by checking TSH; if prolactin remains high, obtain a pituitary MRI to evaluate for pituitary lesions. 28
• Recognize that mild prolactin elevations can occur after seizures; ensure the sample is not drawn in the post‑ictal period to avoid false‑positive results. 28
• An LH/FSH ratio > 2 strongly suggests PCOS; proceed with pelvic ultrasound and consider measuring androgen levels (e.g., testosterone, DHEA‑S) if clinical hyperandrogenism is present. 28

Imaging Studies

• Indications for transvaginal pelvic ultrasound include an LH/FSH ratio > 2, any palpable adnexal mass, or any concern for structural pelvic abnormality. 28
• Indications for pituitary MRI include persistent hyperprolactinemia after thyroid disease has been excluded, as well as the presence of headaches or visual‑field deficits. 28

Red‑Flag Findings

• Severe hirsutism or virilization warrants measurement of serum testosterone; levels > 2.5 nmol/L should prompt evaluation for an androgen‑secreting tumor. 28

Evidence‑Based Findings in the Diagnostic Approach to Amenorrhea

Clinical Signs of Estrogen Deficiency

• Vaginal atrophy and a thin endometrial lining (≤ 5 mm on pelvic ultrasound) are reliable physical signs of hypo‑estrogenism in women with amenorrhea. [29][30]

Hormonal Ratios in Functional Hypothalamic Amenorrhea (FHA)

• An LH/FSH ratio < 1 is observed in approximately 82 % of patients with functional hypothalamic amenorrhea, making it a useful laboratory marker for this condition. [29][30]

Etiology of Functional Hypothalamic Amenorrhea

• The primary precipitating factors for FHA include low energy availability, excessive physical exercise, eating‑disorder behaviors, and significant psychological stress. [29][30]

Differentiating FHA with Polycystic Ovarian Morphology (FHA‑PCOM) from Polycystic Ovary Syndrome (PCOS)

*These contrasting patterns aid clinicians in distinguishing FHA‑PCOM from true PCOS, guiding appropriate management strategies. [29][30]

Long‑Term Complications and Evidence‑Based Management of Premature Ovarian Insufficiency

Diagnosis

• In women under 40 years with amenorrhea, a single measurement showing follicle‑stimulating hormone > 40 IU/L and luteinizing hormone > 40 IU/L in the postmenopausal range confirms premature ovarian insufficiency (POI) 31.
• Normal prolactin and thyroid‑stimulating hormone levels help exclude alternative endocrine disorders when evaluating POI 31.
• Low serum testosterone is consistent with ovarian failure and supports the POI diagnosis 31.
• A definitive POI diagnosis requires two elevated FSH values (> 40 IU/L) obtained at least four weeks apart 32.

Bone Health Risks

• The hypo‑estrogenic state inherent to POI is the primary mechanism driving accelerated bone loss in affected women 31.
• Without prompt estrogen replacement, women with POI face decades of estrogen deficiency during the period when peak bone mass should be preserved, markedly increasing the risk of osteoporosis 31.

Hormone Replacement Therapy (HRT)

• Immediate initiation of physiologic estrogen replacement (e.g., transdermal estradiol) is recommended to prevent further bone loss in women with POI 31.
• Continuation of HRT until at least the natural menopause age (≈ 50–51 years) is advised to maintain bone health and to lower long‑term cardiovascular risk 31.

Adjunctive Supplementation

• Calcium and vitamin D supplementation should be provided to all women with POI unless contraindicated, as part of bone‑protective management 33.

Genetic and Autoimmune Screening

• Women with POI should be screened for the fragile‑X premutation and for autoimmune antibodies (e.g., 21‑hydroxylase or adrenal cortex antibodies) because these conditions are frequently associated with the syndrome 31.

Cancer Risk Assessment

• POI is characterized by hypo‑estrogenism and does not increase the risk of endometrial hyperplasia or cancer; the risk is linked to unopposed estrogen exposure seen in other conditions such as polycystic ovary syndrome 34.
• Current evidence shows no association between POI and an elevated ovarian cancer risk 31.

Limitations of LH/FSH Testing and Ultrasound in Early Post‑Menarchal Adolescents

Ultrasound Use in Early Post‑Menarchal Adolescents

• Ultrasound should not be employed to diagnose polycystic ovary syndrome (PCOS) in girls whose gynecologic age is < 8 years after menarche, because multi‑follicular ovaries are common in this developmental stage, making sonographic findings unreliable for PCOS assessment. Strength of evidence: observational data indicating high false‑positive rate. 35
• Routine ordering of LH and FSH assays in early post‑menarchal adolescents with irregular bleeding is discouraged, as the results are difficult to interpret and often lead to unnecessary downstream investigations. Strength of evidence: expert consensus highlighting limited diagnostic utility. 35

Diagnostic Value of the LH/FSH Ratio

• An LH/FSH ratio > 2 has poor sensitivity for PCOS, being elevated in only 35–44 % of women with confirmed disease, thus it should not be relied upon as a primary diagnostic criterion. Strength of evidence: moderate (based on comparative studies). 36
• When clinical hyperandrogenism is present, measurement of total testosterone is the preferred initial biochemical test (approximately 70 % of PCOS patients show abnormal testosterone), with the LH/FSH ratio considered only as a secondary assessment if PCOS remains suspected. Strength of evidence: moderate (derived from diagnostic accuracy studies). [36][37]
• Isolated polycystic ovarian morphology (PCOM) on ultrasound is observed in 17–22 % of normal adolescent women, indicating that PCOM alone does not confirm PCOS and must be interpreted alongside clinical and biochemical findings. Strength of evidence: moderate (population‑based imaging studies). [36][38]

Management of Premature Ovarian Insufficiency (POI)

Hormone Replacement Therapy (HRT)

• Initiate physiologic estrogen replacement promptly to prevent the long‑term complications of prolonged hypo‑estrogenism, such as bone loss and cardiovascular disease. 39
• Use transdermal estradiol 100 µg patches applied twice weekly; this route provides superior bone protection and a lower risk of thrombotic events compared with oral estrogen. 39
• Add cyclic micronized progesterone 200 mg daily for 12 days each month in women with an intact uterus to protect the endometrium when systemic estrogen is given. 39
• Continue HRT at least until the age of natural menopause (≈ 50‑51 years) to preserve bone health and reduce cardiovascular risk. 39
• The benefit‑risk profile of HRT in POI is favorable, with benefits outweighing minor side effects, unlike in older post‑menopausal women. 39

Risks Associated with Untreated POI

• Women with POI have approximately a two‑fold higher risk of fractures compared with age‑matched healthy women. 39
• About one‑third of POI patients develop endothelial dysfunction, indicating an elevated risk for cardiovascular disease. 39

Bone Health Assessment

• Obtain a baseline dual‑energy X‑ray absorptiometry (DXA) scan immediately to evaluate bone mineral density. 39
• Repeat DXA scanning every 1–2 years to monitor the response to HRT. 39
• Provide calcium and vitamin D supplementation unless contraindicated. 39

Screening for Associated Conditions

• Perform Fragile X (FMR1) premutation testing, as POI is frequently linked to carrier status. 39
• Order an autoimmune antibody panel (e.g., 21‑hydroxylase, adrenal cortex, thyroid antibodies) to identify co‑existing autoimmune disorders. 39
• Consider karyotype analysis to exclude Turner‑syndrome mosaicism when not previously performed. 39

Fertility Counseling

• POI does not equate to absolute infertility; intermittent ovarian activity occurs in 5‑10 % of cases. 39
• For patients desiring pregnancy, refer to reproductive endocrinology for discussion of oocyte donation or the possibility of spontaneous conception. 39

Clinical Pitfalls to Avoid

• Do not attribute amenorrhea solely to intrauterine devices; markedly elevated FSH/LH and low estradiol confirm true ovarian failure. 39
• Do not prescribe combined oral contraceptives in place of physiologic HRT, as they deliver supraphysiologic hormone doses and are less effective for bone protection. 39
• Do not delay initiation of HRT; each month of untreated hypo‑estrogenism leads to irreversible bone loss during the pre‑menopausal years. 39
• Do not discontinue HRT arbitrarily; therapy should be continued until at least the natural menopause age (≈ 50‑51 years). 39

Multidisciplinary Referral

• Refer patients to gynecology or reproductive endocrinology for comprehensive POI management, including HRT optimization, monitoring for rare spontaneous ovarian recovery, psychological support, and discussion of fertility preservation options. 39

Diagnostic Criteria, Hormonal Assessment, and Management of Premature Ovarian Insufficiency (POI)

Definition and Diagnostic Thresholds

• Premature ovarian insufficiency is defined as loss of ovarian activity before age 40 years, presenting with amenorrhea or oligomenorrhea together with elevated gonadotropins (FSH, LH) and low estradiol levels. 40
• Two separate FSH measurements > 25 IU/L (some guidelines use > 40 IU/L) obtained at least 4 weeks apart, combined with low estradiol, confirm the diagnosis of POI. 40
• In POI, serum progesterone remains low because ovulation is absent. 40

Hormonal Profile Distinguishing POI from Perimenopause

• Women < 40 years with consistently elevated FSH/LH (FSH > 25‑40 IU/L) and persistently low estradiol (< 30‑50 pg/mL) are classified as having POI. 40

Effect of Levonorgestrel‑Releasing IUD (Mirena) on Hormone Levels

• Levonorgestrel IUDs release the progestogen locally into the uterine cavity with minimal systemic absorption, so they do not suppress the hypothalamic‑pituitary‑ovarian axis. [40][41]42
• The primary mechanism is local endometrial suppression; ovulation continues in the majority of users. 40
• Serum FSH and LH concentrations remain accurate reflections of true ovarian function because the axis is not suppressed. [41][42]
• Estradiol measurements remain reliable for assessing ovarian estrogen production in Mirena users. 41
• Amenorrhea caused by the Mirena results from endometrial atrophy, not from ovarian failure. [40][41]
• In women < 40 years using a Mirena who develop estrogen‑deficiency symptoms (e.g., hot flashes, vaginal dryness, mood changes), FSH and estradiol should be measured; the results are valid for diagnosing POI. 41

Immediate Management After POI Diagnosis

• Prompt initiation of physiologic estrogen replacement is essential to prevent irreversible bone loss and cardiovascular disease. 42
• When the uterus is intact, add cyclic micronized progesterone (≈200 mg for 12 days per month) because the Mirena does not provide sufficient systemic progesterone for bone or cardiovascular protection. 42
• Continue hormone replacement therapy until the natural menopause age (≈50‑51 years). 42
• Obtain a baseline dual‑energy X‑ray absorptiometry (DXA) scan to assess bone mineral density at diagnosis. 41

Comparative Hormonal Table (Reference 40)

Table derived from Human Reproduction Update 2016 (reference 40).